Literature DB >> 12230510

Functional analysis of the profilaggrin N-terminal peptide: identification of domains that regulate nuclear and cytoplasmic distribution.

David J Pearton1, Beverly A Dale, Richard B Presland.   

Abstract

Profilaggrin is expressed in the differentiating granular layer of epidermis and other stratified epithelia, where it forms a major component of cytoplasmic keratohyalin granules. It consists of two distinct domains, an N-terminal S100-like Ca2+- binding domain containing two EF-hands and multiple filaggrin units that aggregate keratin filaments in the stratum corneum. Here, we report structure-function studies of the N-terminal peptide from mouse, human, and rat profilaggrin. The profilaggrin N- terminal peptides of all species contain two S100-like EF-hands, bipartite nuclear localization sequences, and proprotein convertase cleavage sites. The nuclear localization signals in human and mouse profilaggrin were shown to be functional by transfection of epithelial cells and depended on the absence of filaggrin sequences. The nuclear localization of the processed (free) N-terminal peptide of human profilaggrin is consistent with immunolocalization findings in normal human skin and in parakeratotic skin disorders, which exhibit nuclear staining of granular and/or cornified layers. The mouse profilaggrin N-terminus undergoes proteolytic processing in two steps, first releasing an N-terminal peptide containing some filaggrin sequence and finally the free N-terminus of 28-30 kDa; these peptides have cytoplasmic and nuclear distributions, respectively, when expressed in transfected cells. The N-terminal processing may occur prior to or simultaneously with the proteolytic processing of the polyfilaggrin domain. The nuclear accumulation of the profilaggrin N-terminal peptide in epidermis and in transfected cells strongly suggests a calcium-dependent nuclear function for the profilaggrin N-terminus during epidermal terminal differentia tion when the free N-terminus is released from profilaggrin by specific proteolysis.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12230510     DOI: 10.1046/j.1523-1747.2002.01831.x

Source DB:  PubMed          Journal:  J Invest Dermatol        ISSN: 0022-202X            Impact factor:   8.551


  23 in total

Review 1.  Epidermal barrier dysfunction and cutaneous sensitization in atopic diseases.

Authors:  Akiharu Kubo; Keisuke Nagao; Masayuki Amagai
Journal:  J Clin Invest       Date:  2012-02-01       Impact factor: 14.808

Review 2.  Ichthyosis update: towards a function-driven model of pathogenesis of the disorders of cornification and the role of corneocyte proteins in these disorders.

Authors:  Matthias Schmuth; Robert Gruber; Peter M Elias; Mary L Williams
Journal:  Adv Dermatol       Date:  2007

3.  The Barrier Molecules Junction Plakoglobin, Filaggrin, and Dystonin Play Roles in Melanoma Growth and Angiogenesis.

Authors:  Katie M Leick; Anthony B Rodriguez; Marit M Melssen; Mouadh Benamar; Robin S Lindsay; Rebeka Eki; Kang-Ping Du; Mahmut Parlak; Tarek Abbas; Victor H Engelhard; Craig L Slingluff
Journal:  Ann Surg       Date:  2019-10       Impact factor: 12.969

Review 4.  Protein Arginine Deiminases and Associated Citrullination: Physiological Functions and Diseases Associated with Dysregulation.

Authors:  Erin E Witalison; Paul R Thompson; Lorne J Hofseth
Journal:  Curr Drug Targets       Date:  2015       Impact factor: 3.465

Review 5.  Mechanisms leading from systemic autoimmunity to joint-specific disease in rheumatoid arthritis.

Authors:  Anca I Catrina; Camilla I Svensson; Vivianne Malmström; Georg Schett; Lars Klareskog
Journal:  Nat Rev Rheumatol       Date:  2016-12-15       Impact factor: 20.543

6.  Deimination of human filaggrin-2 promotes its proteolysis by calpain 1.

Authors:  Chiung-Yueh Hsu; Julie Henry; Anne-Aurélie Raymond; Marie-Claire Méchin; Valérie Pendaries; Dany Nassar; Britta Hansmann; Stéfana Balica; Odile Burlet-Schiltz; Anne-Marie Schmitt; Hidenari Takahara; Carle Paul; Guy Serre; Michel Simon
Journal:  J Biol Chem       Date:  2011-04-29       Impact factor: 5.157

7.  Low-dose methotrexate enhances aminolevulinate-based photodynamic therapy in skin carcinoma cells in vitro and in vivo.

Authors:  Sanjay Anand; Golara Honari; Tayyaba Hasan; Paul Elson; Edward V Maytin
Journal:  Clin Cancer Res       Date:  2009-05-15       Impact factor: 12.531

8.  Filaggrin in the frontline: role in skin barrier function and disease.

Authors:  Aileen Sandilands; Calum Sutherland; Alan D Irvine; W H Irwin McLean
Journal:  J Cell Sci       Date:  2009-05-01       Impact factor: 5.285

9.  Knockdown of filaggrin in a three-dimensional reconstructed human epidermis impairs keratinocyte differentiation.

Authors:  Valérie Pendaries; Jeremy Malaisse; Laurence Pellerin; Marina Le Lamer; Rachida Nachat; Sanja Kezic; Anne-Marie Schmitt; Carle Paul; Yves Poumay; Guy Serre; Michel Simon
Journal:  J Invest Dermatol       Date:  2014-06-13       Impact factor: 8.551

10.  A homozygous frameshift mutation in the mouse Flg gene facilitates enhanced percutaneous allergen priming.

Authors:  Padraic G Fallon; Takashi Sasaki; Aileen Sandilands; Linda E Campbell; Sean P Saunders; Niamh E Mangan; John J Callanan; Hiroshi Kawasaki; Aiko Shiohama; Akiharu Kubo; John P Sundberg; Richard B Presland; Philip Fleckman; Nobuyoshi Shimizu; Jun Kudoh; Alan D Irvine; Masayuki Amagai; W H Irwin McLean
Journal:  Nat Genet       Date:  2009-04-06       Impact factor: 38.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.